ArticlePloS one2015
Ex vivo cytosolic delivery of functional macromolecules to immune cells.
Open access · goldAbstract read
In one paragraph
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 61 citations in OpenAlex.
- Quantitative Analysis of Plasmid DNA Distribution and Transgene Expression Following Cell Squeezing.Annals of biomedical engineering · 2026Article
- Mechanisms and Strategies for Enhancing DNA Nuclear Entry in Gene Delivery.Cellular and molecular bioengineering · 2026Article
- Engineering a Microfluidic Platform to Cryopreserve Stem Cells: A DMSO-Free Sustainable Approach.Advanced healthcare materials · 2024Article
- Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.Molecular carcinogenesis · 2024Article
- Development of a microfluidic cell transfection device into gene-edited CAR T cell manufacturing workflow.Lab on a chip · 2023Article
- A high-throughput microfluidic mechanoporation platform to enable intracellular delivery of cyclic peptides in cell-based assays.Bioengineering & translational medicine · 2023Article
- Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.Investigational new drugs · 2023Article
- The cellular response to plasma membrane disruption for nanomaterial delivery.Nano convergence · 2022Review
- Microfluidic mechanoporation for cellular delivery and analysis.Materials today. Bio · 2022Review
- Engineered RBCs Encapsulating Antigen Induce Multi-Modal Antigen-Specific Tolerance and Protect Against Type 1 Diabetes.Frontiers in immunology · 2022Article
- Numerical simulation of intracellular drug delivery via rapid squeezing.Biomicrofluidics · 2021Article
- siRNA Design and GalNAc-Empowered Hepatic Targeted Delivery.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy.Acta pharmaceutica Sinica. B · 2020Review
- Single-Cell Electroporation with Real-Time Impedance Assessment Using a Constriction Microchannel.Micromachines · 2020Article
- Massively-Parallelized, Deterministic Mechanoporation for Intracellular Delivery.Nano letters · 2020Article
- Delivery strategies of cancer immunotherapy: recent advances and future perspectives.Journal of hematology & oncology · 2019Review
- Delivery technologies for cancer immunotherapy.Nature reviews. Drug discovery · 2019Review
- Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding.Scientific reports · 2019Article
- Cell engineering with microfluidic squeezing preserves functionality of primary immune cells in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Microfluidic generation of transient cell volume exchange for convectively driven intracellular delivery of large macromolecules.Materials today (Kidlington, England) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 1 country.
Armon ShareiDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America; The Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America; The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Radiana TrifonovaProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Siddharth JhunjhunwalaThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
George C HartoularosDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Alexandra T EyermanDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Abigail Lytton-JeanThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Mathieu AnginThe Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Siddhartha SharmaThe Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Roberta PoceviciuteDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Shirley MaoDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Megan HeimannDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Sophia LiuDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Tanya TalkarDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Omar F KhanThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Marylyn AddoThe Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Ulrich H von AndrianThe Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America.
Daniel G AndersonDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America; The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Robert LangerDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America; The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Judy LiebermanProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Klavs F JensenDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Massachusetts Institute of Technology · USRagon Institute of MGH, MIT and Harvard · USHarvard University · USBoston Children's Hospital · US
Funding
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Darrell J Irvine · 1985 to 2026
$93.9MP3: Chemokine-Mediated T Cell Trafficking in HIV Transmission and Immune ResponseP01AI112521 · NIAID · HARVARD MEDICAL SCHOOL · PI LUSTER, ANDREW · 2014 to 2018
$9.8MHigh throughput microfluidic intracellular delivery platformR01GM101420 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ANDERSON, DANIEL G, JENSEN, KLAVS F · 2013 to 2016
$2.1MFunctional Roles of Nurr1 for Midbrain Dopamine Neurons in Health and DiseaseR01NS084869 · NINDS · MCLEAN HOSPITAL · PI KIM, KWANG-SOO · 2014 to 2018
$1.7MNCI NIH HHS P30 CA014051NCI NIH HHS P30-CA14051NIAID NIH HHS P01 AI112521NIGMS NIH HHS R01 GM101420NIGMS NIH HHS R01GM101420-01A1NINDS NIH HHS R01 NS084869
Abstract
Intracellular delivery of biomolecules, such as proteins and siRNAs, into primary immune cells, especially resting lymphocytes, is a challenge. Here we describe the design and testing of microfluidic intracellular delivery systems that cause temporary membrane disruption by rapid mechanical deformation of human and mouse immune cells. Dextran, antibody and siRNA delivery performance is measured in multiple immune cell types and the approach's potential to engineer cell function is demonstrated in HIV infection studies.
Indexed as
Lab-On-A-Chip DevicesAnimalsAntibodiesB-LymphocytesCells, CulturedDendritic CellsDextransDrug Delivery SystemsHIVHIV InfectionsHumansMiceMice, Inbred C57BLRNAi TherapeuticsRNA, Small InterferingT-LymphocytesAntibodiesDextransRNA, Small Interfering
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.